

Etanercept (Enbrel®)
Wyeth Pharmaceuticals

No. 107/04

Summary of Recommendation

4 June, 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: following a full submission.

Etanercept (Enbrel®) is accepted for use within NHS Scotland for the treatment of active and progressive psoriatic arthritis in adults. It is the first drug to be licensed for this indication and not only improves symptoms of arthritis and psoriasis, but may slow the progression of joint damage (at least over a period of one year).

Professor David H Lawson
Chairman